Association of anticoagulation dose and survival in hospitalized COVID‐19 patients: A retrospective propensity score‐weighted analysis

Simple item page
dc.citation.journalTitleEuropean Journal of Haematologyen_US
dc.contributor.authorIonescu, Filipen_US
dc.contributor.authorJaiyesimi, Ishmaelen_US
dc.contributor.authorPetrescu, Ioanaen_US
dc.contributor.authorLawler, Patrick R.en_US
dc.contributor.authorCastillo, Edwarden_US
dc.contributor.authorMunoz‐Maldonado, Yolandaen_US
dc.contributor.authorImam, Zaiden_US
dc.contributor.authorNarasimhan, Mangalaen_US
dc.contributor.authorAbbas, Amr E.en_US
dc.contributor.authorKonde, Anishen_US
dc.contributor.authorNair, Girish B.en_US
dc.date.accessioned2020-12-09T14:59:08Zen_US
dc.date.available2020-12-09T14:59:08Zen_US
dc.date.issued2020en_US
dc.description.abstractBackground: Hypercoagulability may contribute to COVID‐19 pathogenicity. The role of anticoagulation (AC) at therapeutic (tAC) or prophylactic doses (pAC) is unclear. Objectives: We evaluated the impact on survival of different AC doses in COVID‐19 patients. Methods: Retrospective, multi‐center cohort study of consecutive COVID‐19 patients hospitalized between March 13 and May 5, 2020. Results: A total of 3480 patients were included (mean age, 64.5 years [17.0]; 51.5% female; 52.1% black and 40.6% white). 18.5% (n = 642) required intensive care unit (ICU) stay. 60.9% received pAC (n = 2121), 28.7% received ≥3 days of tAC (n = 998), and 10.4% (n = 361) received no AC. Propensity score (PS) weighted Kaplan‐Meier plot demonstrated different 25‐day survival probability in the tAC and pAC groups (57.5% vs 50.7%). In a PS–weighted multivariate proportional hazards model, AC was associated with reduced risk of death at prophylactic (hazard ratio [HR] 0.35 [95% confidence interval {CI} 0.22‐0.54]) and therapeutic doses (HR 0.14 [95% CI 0.05‐0.23]) compared to no AC. Major bleeding occurred more frequently in tAC patients (81 [8.1%]) compared to no AC (20 [5.5%]) or pAC (46 [2.2%]) subjects. Conclusions: Higher doses of AC were associated with lower mortality in hospitalized COVID‐19 patients. Prospective evaluation of efficacy and risk of AC in COVID‐19 is warranted.en_US
dc.identifier.citationIonescu, Filip, Jaiyesimi, Ishmael, Petrescu, Ioana, et al.. "Association of anticoagulation dose and survival in hospitalized COVID‐19 patients: A retrospective propensity score‐weighted analysis." <i>European Journal of Haematology,</i> (2020) Wiley: https://doi.org/10.1111/ejh.13533.en_US
dc.identifier.doihttps://doi.org/10.1111/ejh.13533en_US
dc.identifier.urihttps://hdl.handle.net/1911/109634en_US
dc.language.isoengen_US
dc.publisherWileyen_US
dc.rightsThis is an author's peer-reviewed final manuscript, as accepted by the publisher. The published article is copyrighted by Wiley.en_US
dc.titleAssociation of anticoagulation dose and survival in hospitalized COVID‐19 patients: A retrospective propensity score‐weighted analysisen_US
dc.typeJournal articleen_US
dc.type.dcmiTexten_US
dc.type.publicationpost-printen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
AJH-20-1685_Proof_hi-copy.pdf
Size:
1.32 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Rice Coronavirus Research